- Ratio Therapeutics, a radiopharmaceutical developer, has expanded its partnership with Florida-based CDMO PharmaLogic.
- Ratio’s lead candidate, a fibroblast activation protein-alpha (FAP)-targeted radiotherapy for soft tissue sarcoma, is expected to reach the clinic by the end of the year.
Ratio Therapeutics, a developer of radiotherapeutics, has expanded its partnership with Florida-based contract development and manufacturing organisation (CDMO) PharmaLogic. This expansion comes on the heels of a $50 million series B financing round.
The partnership aims to accelerate the development and commercialisation of Ratio’s pipeline of products in the burgeoning field of radiotherapeutics. Ratio’s lead candidate is a fibroblast activation protein-alpha (FAP)-targeted radiotherapy for soft tissue sarcoma, which is slated to reach the clinic by year’s end.
“PharmaLogic puts so much into their infrastructure that we decided to not build just a single-center site as some companies have done in the marketplace,” said Ratio CEO Jack Hoppin, Ph.D. “We see them as a very scalable commercial solution.”
PharmaLogic not only manufactures radiopharmaceuticals but also has a distributing network of compounding pharmacies across the country that handle radioactive drugs. This broad reach is crucial in the distribution of radiopharmaceuticals, which have a short shelf life.
“You’re selling ice cream without a fridge,” Ratio chief scientific officer John Babich, Ph.D., added. “We can meet everyone from Maine to San Diego with our products through [PharmaLogic’s] network.”
Operating in a field that’s attracting significant attention, Ratio has attracted $90 million in funding since coming out of stealth mode in June 2022, including its $50 million Series B round in January.
Overview of outsourcing trends 
